➤ Get the DrugPatentWatch Daily Briefing

Get Daily Updates on Generic Entry, Litigation, Biosimilars, and more …

Serving leading biopharmaceutical companies globally:

Medtronic
Merck
McKinsey
Boehringer Ingelheim
Mallinckrodt
Dow

Last Updated: October 28, 2021

DrugPatentWatch Database Preview

GABAPENTIN Drug Patent Profile


Email this page to a colleague

« Back to Dashboard

Which patents cover Gabapentin, and when can generic versions of Gabapentin launch?

Gabapentin is a drug marketed by Aci Healthcare Ltd, Actavis Elizabeth, Alkem, Amneal Pharms Ny, Ascent Pharms Inc, Aurobindo Pharma Ltd, Cspc Ouyi, Granules, Graviti Pharms, Hikma, Invagen Pharms, Jiangsu Hengrui Med, Marksans Pharma, Mylan, Sandoz, Sciegen Pharms Inc, Strides Pharma, Sun Pharm Inds Ltd, Sun Pharm Industries, Taro, Teva Pharms, Watson Labs, Zhejiang Yongtai, Acella Pharms Llc, Akorn, Amneal Pharms, Tris Pharma Inc, Vistapharm, Alkem Labs Ltd, Apotex Inc, Glenmark Pharms Ltd, Hikma Pharms, Invatech, Ivax Sub Teva Pharms, Lupin Ltd, Mylan Pharms Inc, Ranbaxy, Rubicon, Teva, Teva Pharms Usa, and Zydus Pharms Usa Inc. and is included in fifty-two NDAs.

The generic ingredient in GABAPENTIN is gabapentin. There are twenty-nine drug master file entries for this compound. Seventy-six suppliers are listed for this compound. Additional details are available on the gabapentin profile page.

DrugPatentWatch® Litigation and Generic Entry Outlook for Gabapentin

A generic version of GABAPENTIN was approved as gabapentin by ACTAVIS ELIZABETH on September 12th, 2003.

  Free Forever Trial

Drug patent expirations by year for GABAPENTIN
Drug Prices for GABAPENTIN

See drug prices for GABAPENTIN

Drug Sales Revenue Trends for GABAPENTIN

See drug sales revenues for GABAPENTIN

Recent Clinical Trials for GABAPENTIN

Identify potential brand extensions & 505(b)(2) entrants

SponsorPhase
Eagles Autism FoundationPhase 4
David CochranPhase 4
Thomas Jefferson UniversityPhase 3

See all GABAPENTIN clinical trials

Pharmacology for GABAPENTIN
Anatomical Therapeutic Chemical (ATC) Classes for GABAPENTIN
Paragraph IV (Patent) Challenges for GABAPENTIN
Tradename Dosage Ingredient NDA Submissiondate
GRALISE TABLET;ORAL gabapentin 022544 2011-10-31
NEURONTIN CAPSULE;ORAL gabapentin 020235
NEURONTIN TABLET;ORAL gabapentin 020882
NEURONTIN SOLUTION;ORAL gabapentin 021129

US Patents and Regulatory Information for GABAPENTIN

Applicant Tradename Generic Name Dosage NDA Approval Date TE Type RLD RS Patent No. Patent Expiration Product Substance Delist Req. Exclusivity Expiration
Watson Labs GABAPENTIN gabapentin CAPSULE;ORAL 075485-001 May 11, 2007 DISCN No No ⤷  Free Forever Trial ⤷  Free Forever Trial ⤷  Free Forever Trial
Invatech GABAPENTIN gabapentin TABLET;ORAL 076877-001 Jul 6, 2006 DISCN No No ⤷  Free Forever Trial ⤷  Free Forever Trial ⤷  Free Forever Trial
Mylan GABAPENTIN gabapentin CAPSULE;ORAL 090158-002 Feb 14, 2011 DISCN No No ⤷  Free Forever Trial ⤷  Free Forever Trial ⤷  Free Forever Trial
Invagen Pharms GABAPENTIN gabapentin CAPSULE;ORAL 090705-002 Dec 30, 2009 AB RX No No ⤷  Free Forever Trial ⤷  Free Forever Trial ⤷  Free Forever Trial
>Applicant >Tradename >Generic Name >Dosage >NDA >Approval Date >TE >Type >RLD >RS >Patent No. >Patent Expiration >Product >Substance >Delist Req. >Exclusivity Expiration

Make Better Decisions: Try a trial or see plans & pricing

Serving leading biopharmaceutical companies globally:

Medtronic
Merck
McKinsey
Boehringer Ingelheim
Mallinckrodt
Dow

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.